Will advanced cholangiocarcinoma become a targetable malignancy?

Crit Rev Oncol Hematol

Hematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Lebanon.

Published: March 2021

Cholangiocarcinoma and biliary tract cancers are rare but aggressive tumors that are characterized by an heterogenous molecular and genetic footprint. Genetic aberrations such as FGFR2 fusion and ErBb2 amplification are common in those cancers. Recent studies aimed at exploring the efficacy and benefit of targeted therapy in the treatment of advanced cholangiocarcinoma. Many promising drugs exist and warrant additional investigations. This review will summarize available results and highlight therapeutic strategies incorporated in clinical trials.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2021.103233DOI Listing

Publication Analysis

Top Keywords

advanced cholangiocarcinoma
8
will advanced
4
cholangiocarcinoma targetable
4
targetable malignancy?
4
malignancy? cholangiocarcinoma
4
cholangiocarcinoma biliary
4
biliary tract
4
tract cancers
4
cancers rare
4
rare aggressive
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!